Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma.
1. What is the rationale for the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma, and what are the limitations of this regime? (0:06)
2. What were the aims and design of the ENDURANCE trial? (1:38)
3. What were the major efficacy findings of this trial? (3:12)
4. What was the safety profile of this combination and what were the findings in terms of cardiovascular events? (4:34)
5. Despite these promising findings, multiple myeloma remains incurable. What future strategies are likely to further improve outcomes in the coming years? (5:56)
Speaker disclosure: Shaji Kumar has received research funding for clinical trials to the institution from Celgene, Takeda, Janssen, BMS, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio and Carsgen. He has received consulting/advisory board participation fees to his institution from Celgene, Takeda, Janssen, Abbvie, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Genecentrix and Cellectar.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!